EW - Edwards Lifesciences Q3 sales up 4% earnings up 18%

Edwards Lifesciences (EW) Q3 results:Net sales: $1,140.9M (+4.3%), Transcatheter Aortic Valve Replacement ((TAVR)): $744.6M (+6.4%); Surgical Structural Heart: $203.3M (-0.4%); Critical Care: $180.9M (+0.4%); Transcatheter Mitral and Tricuspid Therapies: $12.1M (+24.7%).Net income: $325.2M (+18.4%); non-GAAP net income: $323.8M (+8.2%); EPS: $0.52 (+20.9%); non-GAAP EPS: $0.51 (+8.5%).2020 guidance: Non-GAAP EPS: $1.85 - 1.95 from $1.75 - 1.95.2020 consensus is non-GAAP EPS of $1.84 on sales of $4.4B.TAVR sales growth expected to return to double digits in 2021.Shares down 2% after hours.Edwards Lifesciences EPS beats by $0.07, beats on revenue

For further details see:

Edwards Lifesciences Q3 sales up 4%, earnings up 18%